Multichannel Liquid Chromatography–Tandem Mass Spectrometry Cocktail Method for Comprehensive Substrate Characterization of Multidrug Resistance-Associated Protein 4 Transporter
- First Online:
- 556 Downloads
To develop a comprehensive substrate-screening method for the ATP-binding cassette (ABC) transporter, and identify new substrates for multidrug resistance-associated protein 4 (MRP4/ABCC4).
Human MRP4-expressing membrane vesicles were incubated with a mixture of 50 compounds, including methotrexate, a known MRP4 substrate. The amounts transported were simultaneously determined by liquid chromatography–tandem mass spectrometry.
From 49 compounds, 12 were identified as substrate candidates for MRP4 in the first screening. The second screening was performed involving the uptake of mixture using single quadrupole multichannel mode, and the third screening was performed involving the uptake of individual compounds using multiple reaction monitoring multichannel mode. As a result, eight substrate candidates were additionally identified. Subsequently, in the fourth step, osmotic pressure-dependent transport was demonstrated for 18 compounds (cefmetazole, piperacillin, rebamipide, tetracycline, ampicillin, benzylpenicillin, bumetanide, cephalosporin C, enalapril, pipemidic acid, furosemide, ceftazidime, pravastatin, hydrochlorothiazide, sulbactam, baclofen, bezafibrate and alacepril) among the 20 substrate candidates, thereby confirming them as MRP4 substrates. By contrast, the uptakes of meloxicam and nateglinide did not depend on osmolarity, indicating that these compounds were not substrates, but bound to MRP4.
The new comprehensive substrate-screening method for ABC transporters allowed the identification of 18 new substrates for MRP4.
Key wordsATP-binding cassette transporter human multidrug resistance-associated protein 4 liquid chromatography–tandem mass spectrometry substrate screening vesicle uptake study
blood–cerebrospinal fluid barrier
central nervous system
liquid chromatography–mass spectrometry
liquid chromatography–tandem mass spectrometry
multiple reaction monitoring
multidrug resistance-associated protein
membrane uptake-index difference
organic anion transporter
- 5.M. Leggas, M. Adachi, G. L. Scheffer, D. Sun, P. Wielinga, G. Du, K. E. Mercer, Y. Zhuang, J. C. Panetta, B. Johnston, R. J. Scheper, C. F.Stewart, J. D. Schuetz. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy Mol. Cell. Biol. 24:7612–7621 (2004).PubMedCrossRefGoogle Scholar
- 9.H. Hasannejad, M. Takeda, K. Taki, H. J. Shin, E. Babu, P. Jutabha, S. Khamdang, M. Aleboyeh, M. L. Onozato, A. Tojo, A. Enomoto, N. Anzai, S. Narikawa, X. L. Huang, T. Niwa, H. Endou. Interactions of human organic anion transporters with diuretics J. Pharmacol. Exp. Ther. 308:1021–1029 (2004).PubMedCrossRefGoogle Scholar
- 12.Y. Deguchi, K. Nozawa, S. Yamada, Y. Yokoyama, R. Kimura. Quantitative evaluation of brain distribution and blood–brain barrier efflux transport of probenecid in rats by microdialysis: possible involvement of the monocarboxylic acid transport system J. Pharmacol. Exp. Ther. 280:551–560 (1997).PubMedGoogle Scholar
- 15.P. R. Wielinga, G. Reid, E. E. Challa, I. van der Heijden, L. van Deemter, M. de Haas, C. Mol, A. J. Kuil, E. Groeneveld, J. D. Schuetz, C. Brouwer, R. A. De Abreu, J. Wijnholds, J. H. Beijnen, P. Borst. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells Mol. Pharmacol. 62:1321–1331 (2002).PubMedCrossRefGoogle Scholar
- 16.G. Reid, P. Wielinga, N. Zelcer, I. van der Heijden, A. Kuil, M. de Haas, J. Wijnholds, P. Borst. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs Proc. Natl. Acad. Sci. U. S. A. 100:9244–9249 (2003).PubMedCrossRefGoogle Scholar
- 30.Q. Tian, J. Zhang, S. Y. Chan, T. M. Tan, W. Duan, M. Huang, Y. Z. Zhu, E. Chan, Q. Yu, Y. Q. Nie, P. C. Ho, Q. Li, K. Y. Ng, H. Y. Yang, H. Wei, J. S. Bian, S. F. Zhou. Topotecan is a substrate for multidrug resistance associated protein 4 Curr. Drug Metab. 7:105–118 (2006).PubMedCrossRefGoogle Scholar
- 34.H. Shindo, K. Kawai, T. Maeda, I. Igarashi, M. Tajima, S. Sugawara. Absorption, distribution, excretion and metabolism of a new cephamycin antibiotic, CS-1170, in various animal species Jpn. J. Chemother. 26:S-599–114 (1978).Google Scholar
- 35.Y. Shioya, E. Kashiyama, K. Okada, N. Kusumoto, Y. Abe, M. Uchida, T. Shimizu. Metabolic fate of the anti-ulcer agent, ( ± )-2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid (OPC-12759): Absorption, distribution and excretion in rats and dogs Iyakuhin Kenkyu 20:522–533 (1989).Google Scholar
- 36.M. Ohkawa, M. Orito, T. Sugata, M. Shimamura, M. Sawaki, E. Nakashita, K. Kuroda. Pharmacokinetics of cefmetazole (CS-1170) in patients with normal and impaired renal function Jpn. J. Chemother. 27:78–86 (1979).Google Scholar
- 37.S. Kishi, N. Ogawa. Phase I clinical trial of the Anti-ulcer Agent, Proamipide (OPC-12759) J. Adult Dis. 19:355–363 (1989).Google Scholar
- 38.S. Ohtsuki, H. Asaba, H. Takanaga, T. Deguchi, K. Hosoya, M. Otagiri, T. Terasaki. Role of blood–brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain J. Neurochem. 83:57–66 (2002).PubMedCrossRefGoogle Scholar